These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16189091)

  • 1. Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis.
    Aslangul E; Ruimy R; Chau F; Garry L; Andremont A; Fantin B
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4144-8. PubMed ID: 16189091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis.
    Aslangul E; Massias L; Meulemans A; Chau F; Andremont A; Courvalin P; Fantin B; Ruimy R
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3615-21. PubMed ID: 17065620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis.
    Lafaurie M; Perichon B; Lefort A; Carbon C; Courvalin P; Fantin B
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2826-30. PubMed ID: 11557476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis.
    Lefort A; Baptista M; Fantin B; Depardieu F; Arthur M; Carbon C; Courvalin P
    Antimicrob Agents Chemother; 1999 Mar; 43(3):476-82. PubMed ID: 10049254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo.
    Lefort A; Arthur M; Garry L; Carbon C; Courvalin P; Fantin B
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2077-80. PubMed ID: 10898678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM;
    J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
    Arias CA; Singh KV; Panesso D; Murray BE
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.
    Hellinger WC; Rouse MS; Rabadan PM; Henry NK; Steckelberg JM; Wilson WR
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1272-5. PubMed ID: 1416826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
    Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
    Gavaldá J; Onrubia PL; Gómez MT; Gomis X; Ramírez JL; Len O; Rodríguez D; Crespo M; Ruíz I; Pahissa A
    J Antimicrob Chemother; 2003 Sep; 52(3):514-7. PubMed ID: 12917251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of single doses of amoxicillin or of amoxicillin-gentamicin for the prevention of endocarditis caused by Streptococcus faecalis and by viridans streptococci.
    Francioli P; Moreillon P; Glauser MP
    J Infect Dis; 1985 Jul; 152(1):83-9. PubMed ID: 3925031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.
    Desbiolles N; Piroth L; Lequeu C; Neuwirth C; Portier H; Chavanet P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3328-33. PubMed ID: 11709304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-resistant enterococci.
    Basker MJ; Slocombe B; Sutherland R
    J Clin Pathol; 1977 Apr; 30(4):375-80. PubMed ID: 404337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.
    Moreillon P; Wilson WR; Leclercq R; Entenza JM
    Antimicrob Agents Chemother; 2007 May; 51(5):1661-5. PubMed ID: 17353251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
    Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
    Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance.
    Spiegel CA; Huycke M
    Arch Intern Med; 1989 Aug; 149(8):1873-5. PubMed ID: 2504123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal action of gentamicin against enterococci that are sensitive, or exhibit low- or high-level resistance to gentamicin.
    Fasola EL; Moody JA; Shanholtzer CJ; Peterson LR
    Diagn Microbiol Infect Dis; 1994 May; 19(1):57-60. PubMed ID: 7956015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level gentamicin-resistant enterococci: in vitro activity of double and triple combinations of antimicrobial drugs.
    Ferrara A; Dos Santos C; Cimbro M
    Chemotherapy; 1996; 42(1):37-46. PubMed ID: 8751265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.